MBBS (U of Adelaide, Australia) 2005, FRACP (RACP, Australia) 2013, PhD (U of Melbourne, Australia) 2018
Medical Oncology, NHG Cancer Institute
Medical Oncology, Tan Tock Seng Hospital
Medical Oncology, Woodlands Hospital
Dr Valerie Heong is a Consultant with the Department of Medical Oncology at Tan Tock Seng Hospital, Singapore. She received her medical degree from the University of Adelaide, Australia and subsequently trained in medical oncology in Melbourne, Victoria, Australia. She obtained a PhD in genetics and molecular biology from the Department of Medical Biology, University of Melbourne, Australia and subsequently moved to Singapore. During her PhD she was awarded the Ovarian Cancer Australia Postgraduate Scholarship and the Bev Gray Ovarian Cancer PhD Scholarship.
Dr Heong is a clinician scientist with a special interest in cancer genetics, breast and gynaecological cancer, drug development and translational research. Her research focuses on development of novel therapeutic agents and biomarker discovery in breast and ovarian cancer. She was awarded the Helene Harris Memorial Trust (HHMT) Fellowship Award and the Yong Siew Yoon Fellowship Award for her research and aims to identify aberrant molecular pathways in breast and ovarian cancer that may potentially be exploited and targeted for therapeutic development to improve patient outcomes. She also has numerous abstract presentations in international congresses and scientific peer reviewed publications.
Publications
1. Development and Analytical Performance of Multiplex Droplet Digital PCR Assays for the Detection of PIK3CA Mutations in Metastatic Breast Cancer Patients
2. Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique.
3. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
4. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
5. Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives
6. A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.
7. A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.
8. PARP Inhibitors in Breast and Ovarian Cancer.
9. Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial
10. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
11. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
12. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
13. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.
14. Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence.
